The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Long-Term Antibiotic Treatment for Lyme Disease Shows No Benefits

Long-Term Antibiotic Treatment for Lyme Disease Shows No Benefits

September 8, 2016 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF
ANTIBIOTICS FOR LYME DISEASE

MARCEL JANCOVIC/SHUTTERSTOCK.COM

For people in whom symptoms of Lyme disease persist beyond the standard course of two to four weeks of antibiotic therapy, longer term antibiotic treatment provides no additional benefits beyond the shorter term course.

You Might Also Like
  • Lyme Disease Not Predictor of Long-Term Physical, Mental Health Issues
  • Diagnosis, Treatment Updates for Lyme Arthritis
  • Lyme Arthritis Treatment Protocols Critical as Lyme Disease Spreads
Explore This Issue
September 2016
Also By This Author
  • Diagnostic Criteria Released for Neuromyelitis Optica Spectrum Disorders

This is the conclusion of a recent study published in the New England Journal of Medicine that builds on a number of previously published randomized clinical trials that show no benefit of prolonged antibiotic treatment in patients with persistent symptoms attributed to Lyme disease.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Like others that came before it, this study provides additional evidence that long-term antibiotic therapy is not associated with improvement in long-standing symptoms that follow a diagnosis of Lyme disease,” says Michael T. Melia, MD, assistant professor of medicine at Johns Hopkins University School of Medicine, Baltimore.

The difference with this study is that it is the first randomized study to examine the effects of long-term antibiotic use for Lyme disease in Europe. Writing in an editorial that accompanied the study, Dr. Melia said that one of the interesting aspects of the study was that it was conducted in Europe, where a different type of Lyme disease (i.e., B. burgdorferi sensu lato, including B. afzelii and B. garinii) circulates compared with the U.S.2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“The infections with these species can manifest differently than do infections from North American species, such as with a longer initial duration of illness,” he stated in the editorial.2

In addition, according to lead author of the study, Bart Jan Kullberg, MD, PhD, professor of medicine and infectious diseases, Radboud University Medical Center, Nijmegen, The Netherlands, it is the largest randomized trial to date to look at this issue.

So what does the study show?

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

PLEASE Study

Dr. Melia

Dr. Melia

The Persistent Lyme Empiric Antibiotic Study Europe (PLEASE) trial was undertaken to evaluate the efficacy of longer term antibiotic treatment for persistent symptoms of Lyme disease.1 Ongoing controversy remains over whether or not longer term antibiotic use is effective in this situation, and, subsequently, clinical practice varies in how patients are treated.

“Previous clinical trials have not shown convincingly that prolonged antibiotic treatment has beneficial effects in patients with persistent symptoms attributed to Lyme disease,” says Dr. Kullberg. “Nonetheless, the debate about this issue has continued.”

In the study, 280 patients with persistent symptoms of Lyme disease were randomized to a 12-week oral course of doxycycline (100 mg twice daily) (n=86), clarithromycin (500 mg twice daily) plus hydroxychloroquine (200 mg twice daily) (n=96) or placebo (n=98). Prior to randomization, all patients received open-label intravenous ceftriaxone (2,000 mg daily) for 14 days.
thr_092016_p18_1
All patients included in the study had symptoms proved to be related to Lyme disease based on the temporal relationship to an erthema migrans rash or by assay-confirmed antibodies for B burgdorferi immunoglobulin G (IgG) or M (IgM). These symptoms included arthritis, arthralgia, cognitive disorders with or without persistent fatigue, dysesthesia, musculoskeletal pain, neuralgia, neuropsychological disorders and sensory disturbances.

Pages: 1 2 3 | Single Page

Filed Under: Conditions Tagged With: antibiotic, Clinical, Lyme Disease, outcome, patient care, Research, rheumatology, TreatmentIssue: September 2016

You Might Also Like:
  • Lyme Disease Not Predictor of Long-Term Physical, Mental Health Issues
  • Diagnosis, Treatment Updates for Lyme Arthritis
  • Lyme Arthritis Treatment Protocols Critical as Lyme Disease Spreads
  • Letters: Detecting Lyme Disease May Require Thorough Testing

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)